CDMO Ardena has successfully acquired Catalent's drug product manufacturing facility in New Jersey, US.
This strategic move will expand the company's footprint in the key North American market, while also strengthening its capacity to handle late-stage and small-scale commercial oral drug product manufacturing.
The acquisition of the Somerset site will also allow Ardena's customers to progress from drug development to commercial manufacturing through the integration of these services.
The advanced drug product manufacturing facility has more than 50,000 sqft of cGMP manufacturing space and specialises in modified release formulations, as well as the handling of highly potent APIs (HPAPIs) and hot melt extrusion.
Through the acquisition, Ardena will take on more than 200 skilled employees, enhancing the company's global development and manufacturing expertise.
Boosting analytical testing capabilities
On top of the acquisition of the Somerset facility, Ardena has expanded the bioanalytical services available to clients throughout North America.
The novel bioanalytical lab, which is situated at the Somerset facility, includes a 2,500 sqft space providing small and large molecule analytical testing services such as LC-MS/MS, qPCR and flow cytometry.
This laboratory is expected to be operational by the third quarter of 2025.
CEO of Ardena, Jeremie Trochu, commented: “The addition of the Somerset facility strengthens our ability to provide tailored, high-quality development and manufacturing solutions to our clients, while accelerating the international expansion of our fast-growing bioanalytical business.”
“We are thrilled to officially welcome the Somerset team into the Ardena family," he added. "Their deep scientific and technical expertise, their impeccable regulatory track record, and unwavering dedication to excellence, align perfectly with our mission of helping clients bring life-changing treatments to patients quickly and efficiently.”